ACT 1613/2025

—·EP3175863: VARIANTS OF C-TYPE NATRIURETIC PEPTIDE

Verfahrensdetails: Status
—
Verfahrensart
Verletzung
Kategorie
Hauptverletzungsklage
Parteien: Kläger
BioMarin Pharmaceutical Inc.
Vertreter: Christian Paul (Jones Day); Tobias Mandler (Jones Day); Pascal Grandé (Jones Day)
Beklagte
Ascendis Pharma A/S
Ascendis Pharma Growth Disorders A/S
Vertreter: Agathe Michel-De Cazotte (Carpmaels & Ransford); Anna Leathley (Carpmaels & Ransford); Daniel Wiese (Carpmaels & Ransford)
Division: Munich LD
Richter: Matthias Zigann · Presiding Judge / Judge-Rapporteur
Andras Kupecz · Legally Qualified Judge
Tobias Pichlmaier · Legally Qualified Judge
Technology: Biotech · Peptide Therapeutics · Biotechnology
Sprache: —
Erste Entscheidung: 2. Juni 2025

Entscheidungen

2025-06-02
Infringement Action
Scheduling order by Munich Local Division (UPC_CFI_18/2025 and UPC_CFI_439/2025, 2 June 2025) setting dates for interim conference (9 January 2026, videoconference) and oral hearing (18 March 2026, Munich) in BioMarin's infringement action against Ascendis Pharma, with counterclaim for revocation. Both proceedings will proceed together; a technically qualified judge will be appointed.
Rechtsfragen:Case management / scheduling (R. 28, 33, 37.2 RoP)Consolidation of infringement action and revocation counterclaim

Dokumente